During the past decade, EMD Serono, Inc. conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "EMD Serono, Inc." are "Multiple Sclerosis" (3 trials) and "Relapsing Multiple Sclerosis" (1 trials). Many other conditions were trialed in "EMD Serono, Inc." in a lesser frequency.

Most popular intervention types in "EMD Serono, Inc." are "Device" (2 trials) and "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "RebiSmart™" (1 trials), "Rebidose®" (1 trials), "Rebif" (1 trials), "Rebif New Formulation Non Titrated" (1 trials) and "Rebif New Formulation Titrated" (1 trials). Other intervention names were less common.

The vast majority of trials in "EMD Serono, Inc." are 4 trials for "All" genders.

Currently, there are NaN active trials in "EMD Serono, Inc.". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in EMD Serono, Inc., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in EMD Serono, Inc., 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".